Disclaimer
The stock market is subject to significant volatility and inherent risks. Investing in stocks involves potential losses and is not guaranteed to generate profits. Prices of stocks can fluctuate unpredictably. We do not give you any buy/sell tips. This article is for Educational purposes only.
Chandan Healthcare IPO is a book-built issue worth ₹107.36 crores, consisting of a fresh issue of 44.52 lakh shares totalling ₹70.79 crores and an offer for sale of 23.00 lakh shares amounting to ₹36.57 crores.
The IPO opens for subscription on February 10, 2025, and closes on February 12, 2025. The allotment is expected to be finalized on February 13, 2025 (Thursday). The IPO will be listed on NSE SME, with a tentative listing date of February 17, 2025 (Monday).
The price band for Chandan Healthcare IPO is ₹151 to ₹159 per share. The minimum lot size for application is 800 shares, requiring a minimum investment of ₹1,27,200 for retail investors. HNIs must apply for at least 2 lots (1,600 shares), amounting to ₹2,54,400.
For detailed insights, and real-time updates on IPO GMP, subscription status, and allotment details, investors can refer to trusted sources like IPO Watch, BSE IPO allotment, or the Chandan Healthcare IPO Red Herring Prospectus (RHP). Staying updated on these key aspects is essential for making informed investment decisions in this IPO.
| IPO Date | February 10, 2025 to February 12, 2025 |
| Listing Date | February 10 |
| Face Value | ₹10 per share |
| Price Band | ₹151 to ₹159 per share |
| Lot Size | 800 Shares |
| Total Issue Size | 67,52,000 shares (aggregating up to ₹107.36 Cr) |
| Fresh Issue | 44,52,064 shares (aggregating up to ₹ 70.79 Cr) |
| Offer for Sale | 22,99,936 shares of ₹10 (aggregating up to ₹36.57 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 2,00,00,000 shares |
| Share Holding Post Issue | 2,44,52,064 shares |
| Market Maker Portion | Share Holding Pre-Issue |
| IPO Open Date | Monday, February 10, 2025 |
| IPO Close Date | Wednesday, February 12, 2025 |
| Basis of Allotment | Thursday, February 13, 2025 |
| Initiation of Refunds | Friday, February 14, 2025 |
| Credit of Shares to Demat | Friday, February 14, 2025 |
| Listing Date | Monday, February 17, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on February 12, 2025 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 800 | ₹1,27,200 |
| Retail (Max) | 1 | 800 | ₹1,27,200 |
| HNI (Min) | 2 | 1,600 | ₹2,54,400 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35.00% of the Net Offer |
| NII (HNI) Shares Offered | Not less than 15.00% of the Net Offer |
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 170.06 | 128.86 | 97.83 | 81.23 |
| Revenue | 167.99 | 177.96 | 137.03 | 119.92 |
| Profit After Tax | 17.42 | 16.36 | 3.59 | -1.09 |
| Net Worth | 41.09 | 27.3 | 23.93 | |
| Reserves and Surplus | 34.31 | 21.16 | 7.37 | 4 |
| Total Borrowing | 51.92 | 42.01 | 21.36 | 16.58 |
Maximizing Opportunities with Chandan Healthcare Limited IPO
The Chandan Healthcare Limited IPO offers an exciting opportunity for investors, with a fresh issue of shares and an offer for sale, aiming to raise ₹107.36 crores. With a price band set between ₹151 and ₹159 per share, the IPO presents a favourable investment opportunity for both retail investors and HNIs.
Investors should stay informed about key details such as subscription status, allotment process, and listing date to make well-timed investment decisions. As with any IPO, it's crucial to evaluate the company's fundamentals, growth prospects, and sectoral performance before investing. Staying updated on reliable sources like IPO Watch and BSE IPO allotment can help investors navigate this opportunity successfully.
Overall, Chandan Healthcare Limited's IPO could be a worthwhile consideration for those looking to diversify their portfolios, but due diligence and careful monitoring are advised given the risks inherent in equity investments.
